CU-T12-9

Catalog No.S2979 Batch:S297901

Technical Data

Formula

C₁₇H₁₃F₃N₄O₂

Molecular Weight

362.31

CAS No.

1821387-73-8

Solubility (25°C)*

In vitro

DMSO

72 mg/mL (198.72 mM)

Ethanol

5 mg/mL (13.8 mM)

Water

Insoluble

In vivo (Add solvents to the product individually and in order)

Clear solution	5% DMSO 1 95% Corn oil	0.45mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 9 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O	3.65mg/ml	Taking the 1 mL working solution as an example, add 50 μL of 73 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

CU-T12-9 is a specific agonist of Toll-like receptor (TLR) 1/2 with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS.

Targets

TLR 1/2 ^[1]
(HEK-Blue hTLR2 SEAP assay)

52.9 nM(EC50)

In vitro

CU-T12-9 specifically induces TLR1/2 activation, and facilitates the TLR1/2 heterodimeric complex formation, which in turn activates the downstream NF-κB signaling.^[1]

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines HEK-Blue hTLR2 cells Concentrations 60 nM Incubation Time 24 h Method Cells were cultured in 200 μl of DMEM supplemented with 10% FBS, 10× penicillin/streptomycin, and 10× l-glutamine. Cells were implanted in 96-well plates (4 × 10<sup>4</sup> cells per well) for 24 hours at 37°C before drug treatment. In the next 24 hours of treatment, medium was removed from the 96-well plate and replaced with 200 μl of supplemented Opti-MEM [0.5% FBS, penicillin (50 U/ml), streptomycin (50 μg/ml), 1× nonessential amino acids] containing 60 nM CU-T12-9, 0.66 nM (1 ng/ml) Pam3CSK4, or 0.77 nM (1 ng/ml) Pam2CSK4 according to the manufacturer’s protocol (InvivoGen), as well as different antibodies (0 to 10 μg/ml), including anti-hTLR1–IgG, anti-hTLR2–IgA, or anti-hTLR6–IgA. A sample buffer (20 μl) from each well of the cell culture supernatants was collected and transferred to a transparent 96-well plate. Each well was treated with 200 μl of QUANTI-Blue buffer and incubated at 37°C for 1 h.

Cell Assay:^{^[1]}

Cell lines
HEK-Blue hTLR2 cells
Concentrations
60 nM
Incubation Time
24 h
Method
Cells were cultured in 200 μl of DMEM supplemented with 10% FBS, 10× penicillin/streptomycin, and 10× l-glutamine. Cells were implanted in 96-well plates (4 × 10<sup>4</sup> cells per well) for 24 hours at 37°C before drug treatment. In the next 24 hours of treatment, medium was removed from the 96-well plate and replaced with 200 μl of supplemented Opti-MEM [0.5% FBS, penicillin (50 U/ml), streptomycin (50 μg/ml), 1× nonessential amino acids] containing 60 nM CU-T12-9, 0.66 nM (1 ng/ml) Pam3CSK4, or 0.77 nM (1 ng/ml) Pam2CSK4 according to the manufacturer’s protocol (InvivoGen), as well as different antibodies (0 to 10 μg/ml), including anti-hTLR1–IgG, anti-hTLR2–IgA, or anti-hTLR6–IgA. A sample buffer (20 μl) from each well of the cell culture supernatants was collected and transferred to a transparent 96-well plate. Each well was treated with 200 μl of QUANTI-Blue buffer and incubated at 37°C for 1 h.

References

[1] Kui Cheng, et al. Sci Adv. 2015;1(3):e1400139.

Selleck's CU-T12-9 has been cited by 2 publications

NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes [ Biomedicine & Pharmacotherapy, 2023, 114638]	PubMed: None
NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-κB/TLR1 axis in Psoriatic Keratinocytes [ Biomed Pharmacother, 2023, 162:114638]	PubMed: 37011486

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.